Large malignant phyllodes tumor of the breast with metastases to the lungs

Alexander Augustyn,1,2 Sunati Sahoo,3 Rachel D. Woolridge2,4
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Department of Pathology; 4Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA

Abstract

Phyllodes tumors of the breast account for less than 0.5% of breast cancers and present mostly commonly in women 45 to 49 years old. The importance in managing fibroepithelial lesions lies in distinguishing fibroadenomas, which are benign, from phyllodes tumors, which can be malignant and require complete surgical excision. We report the case of a 56-year-old female who presented with a rapidly enlarging mass in her right breast 18 cm in maximum dimension that completely effaced the breast and distorted the nipple. The patient underwent a successful total mastectomy after core biopsy revealed a diagnosis of phyllodes tumor. Surgical resection is the primary treatment modality; neoadjuvant and adjuvant therapies remain controversial. Here, we report the case of a large malignant phyllodes tumor metastatic to the lungs, review the literature, and discuss diagnostic modalities and adjunct nonsurgical therapies.

Introduction

Phyllodes tumors (PT) of the breast are uncommon fibroepithelial lesions, accounting for less than 0.5% of breast cancers. Most of them are indistinguishable from benign fibroadenomas and present as smooth, painless breast lumps. In contrast to benign breast lesions, PTs can display a range of biologic behavior including passive behavior similar to fibroadenomas, borderline behavior with local recurrence risks, and malignant behavior with metastatic potential. The metastatic and malignant potential of PTs underscores the importance of distinguishing PTs from fibroadenomas and should be suspected when a patient presents with a large breast mass, a rapidly growing mass, or the patient has a history of prior PT. Breast imaging identifies primary PTs as solid, hypoechoic masses frequently indistinguishable from fibroadenomas, and those that contain cystic areas should raise the suspicion for PT.

Core needle biopsy is recommended for initial diagnosis and primarily to differentiate between phyllodes tumor and fibroadenoma. Sub-classification of PTs as benign, borderline, or malignant based on stromal overgrowth, increased stromal cellularity and pleomorphism, and the number of stromal mitoses on a core biopsy is not easily achieved due to limited tumor sampling. Thus, core needle biopsy diagnosis of PTs is associated with a high false negative rate and excisional biopsy is usually required to make a definitive diagnosis. Histopathologic analysis reveals the characteristic appearance of leaf-like architecture that consists of long, cleft-like spaces and papillary projections of hyperplastic or atypical epithelial-lined cellular stroma, increased stromal overgrowth and mitoses consistently predicting malignant and metastatic potential.

Treatment for PTs is primarily surgical, with current guidelines indicating excisional biopsy or partial mastectomy for tumors less than 5 cm in greatest diameter and total mastectomy for those greater than 5 cm. Ancillary nodal sampling is not required because lymph node involvement is very rare, even in the case of large, malignant tumors. Approximately 20% of PTs are considered giant with an arbitrary size greater than 10 cm in diameter and a discussion exists as to the prognostic significance of this cutoff.

Case Report

A 56-year-old woman presented in February 2013 with a large breast mass that exhibited skin changes and had significantly increased in size over the past 4 months. Her past medical history was significant for hypertension, high cholesterol, and arthritis of the right knee. Her past surgical history revealed a hysterectomy at age 42 and two cesarean section deliveries. There was no family history of breast cancer. Menarche was at age 9 and she was a gravida 6, para 4.

On physical examination, our patient was a well-developed, well-nourished female with an obvious right breast mass. At the time of presentation the mass measured 18 cm in greatest dimension. The skin was bright blue, although still visible, and was stretched over the mass such that it was difficult to distinguish the nipple from other areas of skin. At the time of surgery, her nipple-areolar complex became grossly necrotic (Figure 1). No axillary, mediastinal, or clavicular lymphadenopathy was appreciated and the contralateral breast was grossly normal.

Ultrasound examination of the right breast revealed a large, lobulated solid mass that was hypoechoic and involved the entire central right breast. Cystic components were identified. There was associated skin thickening anteriorly and internal vascularity was noted within the mass.

Ultrasound-guided core needle biopsy identified a phyllodes tumor with areas of ischemic necrosis and focal squamous metaplasia of the ductal epithelium. The stroma was moderately cellular with mild-to-moderate nuclear pleomorphism. The stromal mitoses varied from 5 to 6 per 10 high power fields (Figure 2A,B). As per the current guidelines, the tumor was interpreted as at least a borderline PT.

Computed tomography (CT) scan of the chest at the time of diagnosis did not reveal any pulmonary metastatic disease or any other significant findings in the abdomen. Thoracic nodal basins were unremarkable, suggesting that the patient was free of grossly metastatic disease upon presentation.

A standard right total mastectomy was performed excising all thinned skin out of concern for viability. The pectoralis fascia was also removed. Extensive vascularity was noted throughout the tumor, although all bleeding...
vessels were easily managed with standard techniques. No invasion of the pectoralis muscles or axillary lymphadenopathy was noted at the time of surgery. No axillary nodal sampling was performed. The wound was irrigated and a #19 round Blake drain was inserted in the anterior axillary line, followed by closure of the incision with absorbable suture.

Gross examination of the mastectomy specimen revealed a 22×15 cm firm, rubbery, and well-circumscribed tan mass with areas of hemorrhage and necrosis. Microscopic examination identified a fibroepithelial tumor with prominent stromal overgrowth, hypercellular stroma, and multifocal tumor necrosis admixed with hyaline and myxoid degeneration. Stromal cells showed moderate cytologic atypia with increased mitoses – up to 20 per 10 high power fields, consistent with a diagnosis of malignant phyllodes tumor (Figure 2C-E). All surgical margins were negative.

The patient underwent adjuvant radiotherapy. She remained progression-free until an interval chest X-ray and subsequent chest CT performed one year after surgical resection identified multiple pulmonary nodules that were consistent with metastatic disease (Figure 3A). She had no evidence of chest wall or skin recurrence. Five lesions were detected in the right lung and six in the left. A CT-guided core needle biopsy of a lung nodule identified metastatic disease such as the one described (Figure 3B,C). At the time of this report, the patient declined chemotherapeutic intervention and is receiving palliative treatment.

**Discussion**

Phyllodes tumors are rare biphasic breast tumors consisting of epithelial and stromal components, with the latter representing the neoplastic process. The classic presentation is indistinguishable from fibroadenoma as patients present with a firm, mobile, well-defined, lobulated, and painless mass. Similarly, no pathognomonic features are apparent on mammography or ultrasound so the differentiation between fibroadenoma and PT must be made histologically following tissue biopsy. Current research suggests that MRI may be useful in differentiating PT from fibroadenoma based on the presence of lobulation, cystic components, and heterogeneity on delayed-phase contrast-enhanced T1-weighted imaging. Early identification is of utmost importance in order to prevent the development of giant, malignant, and ultimately metastatic tumors such as the one described in the preceding case report. Preoperative core needle biopsy has a sensitivity of 75% in separating PT from fibroadenoma, therefore, any solid mass that was previously deemed benign but subsequently became symptomatic or exhibited rapid growth would necessitate excisional biopsy.

Several reports indicate that adjunct immunohistochemical analysis of MIB-1 (Ki-67), p53, and p63 may improve diagnostic accuracy, but the expression of those and various other tumor markers has failed to predict outcomes. Most recently, expression of CD117 (KIT) was shown to be associated with unfavorable pathologic criteria and worse prognosis in patients with PT, although no mutations in the CD117 gene were identified. A novel development in PT research is the identification of microRNA-21 as an independent prognostic predictor of recurrence and metastasis, and miR-21’s role as an accelerator of PT growth and metastasis is currently being explored.

Nonsurgical therapies for PTs remain controversial and uncertain. Current guidelines from the National Comprehensive Cancer Network (NCCN) indicate that malignant PTs be treated as sarcomas rather than typical breast carcinomas, although no randomized studies of adjuvant chemotherapy currently exist. An observational study followed 28 patients with PTs assigned to either doxorubicin plus dacarbazine or observation alone following surgical resection; this study did not identify any difference in relapse-free survival between the two groups. Due to the general insensitivity of most advanced sarcomas to chemotherapy agents, it is unlikely that chemotherapeutic combination treatment will significantly decrease the rate of relapse or improve survival. Neoadjuvant treatment was reported in one isolated case, with the patient demonstrating no response after three cycles of doxorubicin prior to surgical resection. Emphasis is being placed on the development of patient-specific targeted agents. Whole
Conclusions

The rarity of PTs relative to fibroadenomas makes diagnosis a challenge. Suspicion should be raised when a patient presents with a large mass, a rapidly growing mass, or has a history of prior PT. On breast imaging, PTs may have cystic components but no pathognomonic feature is distinguishable leaving biopsy as the only reliable modality for accurate distinction between PTs and fibroadenomas. PTs are primarily treated with surgical resection to either tumor-free or negative margins. Adjuvant treatment for PTs is currently limited to radiation therapy as chemotherapeutic intervention has consistently proven ineffective while genomic-level research performed on resected phyllodes tumors has the potential to identify novel drug targets in the future.

References

1. Bernstein I, Deapen D, Ross RK. The descriptive epidemiology of malignant cystosarcoma phyllodes tumors of the breast. Cancer 1993;71:3020-4.
2. Chaney AW, Pollack A, McNeese MD, et al. Primary treatment of cystosarcoma phyllodes of the breast. Cancer 2000;89:1502-11.
3. Mangi AA, Smith BL, Gadd MA, et al. Surgical management of phyllodes tumors. Arch Surg 1999;134:487-92.
4. Lee AH. Recent developments in the histological diagnosis of spindled cell carcinoma, fibromatoses and phyllodes tumour of the breast. Histopathology 2008;52:45-57.
5. Dillon MF, Quinn CM, McDermott EW, et al. Needle core biopsy in the diagnosis of phyllodes neoplasms. Surgery 2006;140:779-84.
6. Lee AH, Hodi Z, Ellis IO, Elston CW. Histological features useful in the distinction of phyllodes tumour and fibroadenoma on needle core biopsy of the breast. Histopathology 2007;51:336-44.
7. Pietruszka M, Barnes L. Cystosarcoma phyllodes: a clinicopathologic analysis of 42 cases. Cancer 1978;41:1974-83.
8. Jang JH, Choi MY, Lee SK, et al. Clinicopathologic risk factors for the local recurrence of phyllodes tumors of the breast. Ann Surg Oncol 2012;19:2612-7.
9. MacDonald OK, Lee CM, Tward JD, et al. Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer 2006;107:2127-33.
10. Spitaleri G, Toesca A, Botteri E, et al. Breast phyllodes tumor: a review of literature and a single center retrospective series analysis. Crit Rev Oncol Hematol 2013;84:427-36.
11. Chen WH, Cheng SP, Tzen CY, et al. Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases. J Surg Oncol 2005;91:185-94.
12. Roberts N, Runk DM. Aggressive malignant phyllodes tumor. Int J Surg Case Rep 2015;8C:161-5.
13. Reinfuss M, Mitus J, Duda K, et al. The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases. Cancer 1996;77:910-6.
14. Cohn-Cedermark G, Rutqvist LE, Rosendahl I, Silfversvard C. Prognostic factors in cystosarcoma phyllodes. A clinicopathologic study of 77 patients. Cancer 1991;68:2017-22.
15. Tan PH, Tse G, Lee A, et al. Fibroepithelial tumours. In: Lakhani SR, Ellis IO, Schnitt SJ, et al, eds. WHO classification of tumours of the breast. Lyon: IARC Press; 2012. pp 142-147.
16. Kamitani T, Matsuo Y, Yabuuchi H, et al. Differentiation between benign phyllodes tumors and fibroadenomas of the breast on MR imaging. Eur J Radiol 2014;83:1344-9.
17. Jacklin RK, Ridgway PF, Ziprin P, et al. Optimising preoperative diagnosis in phyllodes tumour of the breast. J Clin Pathol 2006;59:454-9.
18. Ridgway PF, Jacklin RK, Ziprin P, et al. Perioperative diagnosis of cystosarcoma phyllodes of the breast may be enhanced by MIB-1 index. J Surg Res 2004;122:83-8.
19. Carter BA, Page DL. Phyllodes tumor of the breast: local recurrence versus metastatic capacity. Hum Pathol 2004;35:1051-2.
20. Tan WJ, Thike AA, Tan SY, et al. CD117 expression in breast phyllodes tumors correlates with adverse pathologic parameters and reduced survival. Mod Pathol 2015;28:352-8.
21. Gong C, Nie Y, Qu S, et al. miR-21 induces myofibroblast differentiation and promotes the malignant progression of breast phyllodes tumors. Cancer Res 2014;74:4341-52.
22. Theriault RL, Carlson RW, Alred C, et al. Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2013;11:753-60.
23. Morales-Vasquez F, Gonzalez-Angulo AM, Broglio K, et al. Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast.
Breast J 2007;13:551-6.
24. Korpanty G, Power DG, Murphy C, et al. Phyllodes tumor of the breast. Med Oncol 2011;28:S62-4.
25. Jardim DL, Conley A, Subbiah V. Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities. Orphanet J Rare Dis 2013;8:112.
26. Chaney AW, Pollack A, McNeese MD, Zagars GK. Adjuvant radiotherapy for phyllodes tumor of breast. Radiat Oncol Investig 1998;6:264-7.
27. Gnerlich JL, Williams RT, Yao K, et al. Utilization of radiotherapy for malignant phyllodes tumors: analysis of the National Cancer Data Base, 1998-2009. Ann Surg Oncol 2014;21:1222-30.